相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients
Kai Wille et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2022)
Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis
Marko Lucijanic et al.
WIENER KLINISCHE WOCHENSCHRIFT (2022)
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States
Srdan Verstovsek et al.
LEUKEMIA & LYMPHOMA (2022)
Renal disease associated with chronic myeloproliferative neoplasms
Marko Lucijanic et al.
EXPERT REVIEW OF HEMATOLOGY (2022)
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
Marko Lucijanic et al.
LEUKEMIA RESEARCH (2022)
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
Ivan Krecak et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2022)
Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication With Adverse Outcomes in Older Cancer Patients
Li-Ju Chen et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2021)
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera
Ivan Krecak et al.
ANNALS OF HEMATOLOGY (2021)
Quality of Life in Myeloproliferative Neoplasms Symptoms and Management Implications
Ruben Mesa et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Beneficial effect of ACE inhibitors on kidney function in polycythemia vera
Ivan Krecak et al.
WIENER KLINISCHE WOCHENSCHRIFT (2021)
No Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera
Ivan Krecak et al.
ONCOLOGY RESEARCH AND TREATMENT (2021)
Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera
Ivan Krecak et al.
LEUKEMIA & LYMPHOMA (2020)
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca et al.
BLOOD (2020)
Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera
Ivan Krecak et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Salvatrice Mancuso et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
Marko Lucijanic et al.
ANNALS OF HEMATOLOGY (2020)
Associations Between Potentially Inappropriate Medications and Adverse Health Outcomes in the Elderly: A Systematic Review and Meta-analysis
Xiao Xuan Xing et al.
ANNALS OF PHARMACOTHERAPY (2019)
Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
Nana Brochmann et al.
CLINICAL EPIDEMIOLOGY (2019)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
The epidemiology of polypharmacy in older adults: register-based prospective cohort study
Lucas Morin et al.
CLINICAL EPIDEMIOLOGY (2018)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries
Anna Renom-Guiteras et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Elizabeth D. Kantor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study
Sarah Farmer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit criteria
Chirn-Bin Chang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Gastroduodenal lesions in polycythaemia vera:: frequency and role of Helicobacter pylori
G Torgano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)